MOUNTAIN VIEW, Calif., Oct. 11 /PRNewswire/ — IRIDEX
Corporation (Nasdaq:
IRIX) today announced commercial availability of a new family
of Adjustable & Intuitive EndoProbe laser handpieces for use
with the Company’s laser platforms in vitreoretinal surgery. The
Adjustable & Intuitive Laser Probes speed up treatments by
allowing continuous, intuitive adjustment of the fiber optic over a
wide range of angles for full coverage of the peripheral retina
without requiring removal and reinsertion of the probe from the eye
or requiring frequent adjustments of laser power settings. In
addition, its innovative design and construction allows surgeons to
treat further away from the retina and/or at a lower power
setting.
“The introduction of this product under a newly issued U.S.
patent reinforces our strategy of building upon our position as the
global leader in laser delivery instrumentation and to continue to
increase the value of our consumable instrumentation line,” said
Theodore A. Boutacoff, President and CEO.
“We will continue to focus on introducing new products that
differentiates us from our competitors and leverage our existing
sales channel to increase our revenues.”
This product is protected by U.S. Patent No. 7,766,904,
“Adjustable Laser Probe For Use In Vitreoretinal Surgery.” This
patent applies to a number of consumable medical devices already in
the IRIDEX product line, collectively identified and sold as
Adjustable and Intuitive EndoProbe® laser handpieces.
About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader
in developing, manufacturing, and marketing innovative and
versatile laser-based medical systems and delivery devices. We
provide solutions for multiple specialties, including
ophthalmology, dermatology and otolaryngology. We maintain a deep
commitment to the success of our customers, wi
‘/>”/>
SOURCE